RBC Capital Markets Raises Price Target on Acadia Pharmaceuticals
RBC Capital Markets increased its price target for Acadia Pharmaceuticals to $41 from $31 while maintaining an Outperform rating.
Stocks · News reference
Crude Oil Rises Over 4%; Darden Earnings Miss Views
U.S. stocks fell Thursday: Dow -0.7%, S&P 500 -0.46%, Nasdaq -0.7%. Oil jumped 4.4%; Darden missed estimates, while APUS surged 163%.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Surrozen, Inc. Schedules Third Quarter 2026 Earnings Announcement
Surrozen, Inc. has scheduled the release of its financial results for the third quarter of 2026 for November 11, 2026.
RBC Raises Price Target on ACADIA Pharmaceuticals to $38 From $36
RBC Capital Markets increased its price target for Acadia Pharmaceuticals to $38 from $36 while maintaining an 'Outperform' rating, citing continued momentum for the drug Daybue.
Darden Restaurants Plans New Capital Grille and Yard House Locations in Arizona
Darden Restaurants has announced plans to open new freestanding Capital Grille and Yard House locations at the SanTan Crossing development in Arizona.
Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
Acadia Pharmaceuticals announced its financial results for the third quarter ended September 30, 2026, reporting total revenues of $342 million.
ACADIA Pharmaceuticals Q3 EPS $0.31 Beats $0.20 Estimate, Sales $342.291M Beat $332.468M Estimate